CollPlant Biotechnologies Ltd. has announced that researchers at Mayo Clinic have developed the first fully humanized 3D bioprinted skin model using CollPlant's plant-derived recombinant human collagen (rhCollagen). According to a scientific article published in the Archives of Dermatological Research, the new model combines rhCollagen-based bioinks with essential human skin cells, offering a promising alternative to animal testing in preclinical research. The bioprinted skin platform is designed for applications in cosmetic and pharmaceutical testing, disease modeling, and drug development, and can be integrated into a skin-on-a-chip system for evaluation of topical and transdermal drug delivery. The results have already been published and present significant advantages, including high-throughput production of personalized human skin models and potential uses in regenerative medicine.